Physician profile
Robert Saunders
NPI 1265409809
$2,780.08
in general payments reported to CMS, 2019-2025
31 companies · $212 in 2025
The $212 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,290 · 2020: $149 · 2021: $200 · 2022: $441 · 2023: $274 · 2024: $213 · 2025: $212.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $699.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $699.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medical Device Business Services, INC. | $847.21 | 2019 | |
| Astellas Pharma US INC | $299.54 | 2019-2025 | Veozah |
| Abbvie INC. | $243.74 | 2019-2024 | Orilissa |
| Teva Pharmaceuticals USA, INC. | $237.84 | 2022 | |
| Mayne Pharma Commercial LLC | $169.04 | 2021-2025 | |
| Sumitomo Pharma America, INC. | $144.74 | 2023-2025 | Myfembree, Gemtesa |
| Ethicon US, LLC | $122.67 | 2019 | |
| Avion Pharmaceuticals | $91.98 | 2019-2021 | |
| Pfizer INC. | $62.66 | 2019-2025 | |
| Exeltis, USA INC. | $52.22 | 2020-2024 | Slynd |
| Allergan, INC. | $50.38 | 2019-2020 | |
| Roche Diagnostics Corporation | $46.49 | 2021 | |
| Urovant Sciences INC | $41.78 | 2022 | |
| Boston Scientific Corporation | $37.38 | 2025 | General - Female Sui |
| Sage Therapeutics, LLC | $37.00 | 2025 | Zurzuvae |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $35.73 | 2022-2023 | Wegovy |
| Duchesnay USA Incorporated | $25.99 | 2019 | |
| Axonics, INC. | $25.60 | 2024 | Axonics, Bulkamid |
| Becton, Dickinson and Company | $24.35 | 2020 | |
| Organon LLC | $22.87 | 2023 | Nexplanon |
| Hologic Sales and Service, LLC | $20.85 | 2024 | Myosure Tissue Removal Device |
| Supernus Pharmaceuticals, INC. | $19.01 | 2025 | Qelbree |
| Shield Therapeutics INC | $15.72 | 2023 | Accrufer |
| Evofem Biosciences, INC. | $15.60 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.59 | 2019 | |
| Coopersurgical, INC. | $14.30 | 2022 | |
| Pacira Pharmaceuticals Incorporated | $13.14 | 2023 | Exparel |
| Therapeuticsmd, INC. | $12.40 | 2020 | |
| Lupin INC. | $11.90 | 2019 | |
| Merck Sharp & Dohme LLC | $11.49 | 2019 | |
| Medtronic USA, INC. | $10.87 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Saunders listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.